Association between continuous glucose monitoring and health-related quality of life: evidence from rural primary-care patients
Published
May 3, 2024
Paper ID
PAP-000174
Status
Published
DOI
10.65712/tmj.test000432
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on continuous glucose monitoring. Methods: Missing data were handled with multiple imputation. Results: Serious adverse events were rare and similar between groups. 3816 participants were included (median age 38 years). Conclusion: Residual confounding cannot be excluded.
Introduction
health-related quality of life remains a leading cause of avoidable harm among rural primary-care patients. Guidelines make only a weak recommendation on continuous glucose monitoring. The cost of health-related quality of life to health systems is substantial.
Practice around continuous glucose monitoring varies widely between centres. health-related quality of life remains a leading cause of avoidable harm among rural primary-care patients.
Discussion
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.
Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Residual confounding cannot be excluded.
These findings suggest that continuous glucose monitoring is associated with better health-related quality of life in rural primary-care patients. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Conclusions
Continuous glucose monitoring may be offered for rural primary-care patients to improve health-related quality of life.
References
1. Kowalski N, Nakamura I, et al. Pharmacist-led medication review and ventilator-free days. Eur Heart J. 2014;145(3):537-1321.
2. Lindqvist C, Kowalski P, et al. High-flow nasal oxygen and patient satisfaction. JAMA. 2015;358(9):155-1405.
3. Nakamura U, Novak Y, et al. Nurse-led discharge planning and patient satisfaction. Crit Care Med. 2018;212(4):297-918.
4. Larsen W, Patel F, et al. Home-based cardiac rehabilitation and 30-day readmission. Ann Intern Med. 2016;396(6):663-967.
5. Nasser B, Silva C, et al. Nurse-led discharge planning and post-operative delirium. Crit Care Med. 2018;345(10):457-1284.
6. Farouk L, Larsen P, et al. Low-dose aspirin and ventilator-free days. Pediatrics. 2015;384(3):134-1578.
7. Dubois S, Andersen H, et al. SGLT2 inhibitors and emergency department revisits. BMC Med. 2017;193(7):182-988.
8. Ahmed Q, Ahmed F, et al. An antibiotic stewardship programme and patient satisfaction. Eur Heart J. 2019;287(12):411-1245.
9. Herrera X, Mensah W, et al. Early enteral nutrition and post-operative delirium. JAMA. 2013;77(9):9-1104.
10. Yilmaz K, Nasser M, et al. SGLT2 inhibitors and health-related quality of life. BMJ. 2017;306(5):447-1030.
Appendices
Supplementary tables are available on request.
Materials and Methods
Eligible participants were rural primary-care patients. Analyses were adjusted for age, sex and baseline severity.
The primary outcome was health-related quality of life, assessed blind to allocation. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were rural primary-care patients. The primary outcome was health-related quality of life, assessed blind to allocation.
We conducted a retrospective cohort study across 4 centres between 2020 and 2022. We conducted a retrospective cohort study across 5 centres between 2017 and 2022. Analyses were adjusted for age, sex and baseline severity.
Results
1662 participants were included (median age 63 years). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.
4582 participants were included (median age 32 years). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.
health-related quality of life occurred in 4% of the intervention group versus 28% of controls. Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Male | 679 | 109 | 37.5 | 0.59 | 0.57–1.3 |
| Age < 65 | 262 | 66 | 12.6 | 0.94 | 0.20–1.28 |
| Centre B | 794 | 59 | 27.8 | 0.56 | 0.32–1.19 |
| Male | 757 | 52 | 13.2 | 0.89 | 0.52–1.39 |
| Male | 86 | 85 | 13.1 | 0.78 | 0.23–1.31 |
| Centre A | 115 | 114 | 21.0 | 0.54 | 0.46–1.3 |
Values are n (%) unless stated otherwise.

Shown for rural primary-care patients; error bars are 95% confidence intervals.
4357 participants were included (median age 79 years). health-related quality of life occurred in 22% of the intervention group versus 28% of controls. health-related quality of life occurred in 9% of the intervention group versus 14% of controls. The adjusted odds ratio was 0.75 (95% CI 0.46 to 0.83).